Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eli Lilly and : Goldman Sachs Adjusts Eli Lilly's Price Target to $270 From $252, Keeps Conviction Buy Rating

06/14/2021 | 09:25am EDT


ę MT Newswires 2021
All news about ELI LILLY AND COMPANY
10:33aELI LILLY AND : Goldman Sachs Adjusts Price Target for Eli Lilly and Company to ..
MT
10:31aELI LILLY AND : JPMorgan Adjusts Price Target for Eli Lilly and Company to $300 ..
MT
10:30aELI LILLY AND : Mizuho Securities Adjusts Eli Lilly's Price Target to $279 From ..
MT
08:11aELI LILLY AND : Morgan Stanley Adjusts Eli Lilly's Price Target to $275 From $20..
MT
08/04ELI LILLY AND : Planning to Seek US Nod for Alzheimer's Drug to Compete Against ..
MT
08/03ELI LILLY AND : & CO Management's Discussion and Analysis of Results of Operatio..
AQ
08/03Global markets live: Sanofi, Alphabet, BMW, Ford, Tencent...
08/03ELI LILLY AND : Reports Higher Second-Quarter Results But Lowers 2021 Estimates ..
MT
08/03Today on Wall Street: Corporate profits rise by a level not seen since 2009
08/03SECTOR UPDATE : Health Care Stocks Flat To Higher Pre-Bell Tuesday
MT
More news
Financials (USD)
Sales 2021 27 147 M - -
Net income 2021 6 530 M - -
Net Debt 2021 11 365 M - -
P/E ratio 2021 35,8x
Yield 2021 1,33%
Capitalization 232 B 232 B -
EV / Sales 2021 8,97x
EV / Sales 2022 8,66x
Nbr of Employees 35 000
Free-Float 99,8%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 255,99 $
Average target price 248,50 $
Spread / Average Target -2,93%
EPS Revisions
Managers and Directors
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
ELI LILLY AND COMPANY51.62%232 701
JOHNSON & JOHNSON10.81%459 079
ROCHE HOLDING AG14.16%340 492
PFIZER, INC.24.10%255 703
NOVARTIS AG-0.20%224 638
NOVO NORDISK A/S36.67%213 138